RO-104, A First/Best-In-Class Trispecific Monotherapy with the Potential to Offer Superior & Sustained Vision for Wet AMD & DME Patients
Time: 11:30 am
day: Day One
Details:
- Leveraging the RevMod platform with fully human phage display library to identify novel CDRs instrumental in treating diseases of significant unmet need in ophthalmology and oncology
- Looking at the lead ophthalmology asset from RevMod platform, a fully human trispecific antibody (RO-104) targeting 3 clinically validated pathways in AMD and DME as monotherapy, potentially offering superior and sustained vision over standard of care
- Demonstrating early efficacy, safety, and tolerability of RO-104 across multiple animal (rat and NHP) models with a robust FIH study planned to start in Q4 2025 and designed to enable accelerated development path to pivotal trials and registration
